Rucaparib Receives Full FDA Approval for BRCA-Mutated Prostate Cancer
In this article
A New Standard for BRCA-Mutated Prostate Cancer: Full FDA Approval for Rucaparib
On 17 December 2025, the FDA granted rucaparib (Rubraca) full approval for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with AR-targeted therapy and carrying BRCA mutations . This approval converts the previous accelerated approval to regular approval and strengthens the role of PARP inhibitors in prostate cancer.
Key message: In mCRPC patients carrying BRCA1/2 mutations, rucaparib reduces progression risk by 50% compared with standard chemotherapy or a second ARPI treatment.
1) About the Approval and TRITON3
FDA approval is based on a comparison of rucaparib with physician’s choice of treatment (docetaxel or ARPI) in TRITON3. The study demonstrated a marked advantage, particularly in patients with germline or somatic BRCA1, BRCA2 mutations.
2) Patient Selection and Dosage
Patients should be selected using an FDA-approved companion diagnostic test .
• Dose: 600 mg twice daily (2 tablets of 300 mg).
• Criterion: Patients who previously received an ARPI (abiraterone/enzalutamide) but have not received chemotherapy in the mCRPC setting.
3) Efficacy: rPFS (Median, Months)
Hazard Ratio (HR): 0.50. (p < 0.0001). Overall survival (OS) was 23.2 months in the rucaparib arm and 21.2 months in the control arm, without reaching statistical significance.
4) Safety Profile (Most Common Adverse Effects)
| Adverse Effect | All Grades | Grade 3-4 |
|---|---|---|
| Fatigue (Weakness) | 61% | 7% |
| Anemia / Decreased Hb | 47% | 24% |
| Nausea | 50% | <1% |
| Neutropenia | 20%+ | 7% |
Critical Clinical Notes
ATM Mutations: Exploratory analyses showed that rucaparib was not as effective in ATM-mutated patients (HR 0.95) as in BRCA-mutated patients. Benefit comes primarily from the BRCA group.
Hematologic Monitoring: The Grade 3–4 anemia rate is high, at 24%. Monitoring complete blood counts during treatment is vital.
Use Before Chemotherapy: This approval demonstrates that rucaparib is an effective option before docetaxel as well.
DROZDOGAN Academy Commentary
The TRITON3 results show that, in mCRPC, genomic testing is now a necessity rather than a luxury. In patients with identified BRCA mutations, rucaparib can hold back disease progression for twice as long. The limited response in ATM mutations highlights the importance of a personalized approach to PARP inhibitor selection based on mutation type.
Source: FDA.gov, 17 December 2025; TRITON3 Trial (NCT02975934); NEJM 2023.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.